4129 |
PCSK9 in Patients with Recent ACS |
Yi Zhang |
Apr. 12. 21 |
4128 |
Patient Outcomes in Long-Term LDL-C Management: Role of Imaging, Protocols and Guidelines |
Yoshiyasu Minami |
Apr. 12. 21 |
4127 |
Recent Update in Lipid Management for ACS Patients |
Hyunjong Lee |
Apr. 12. 21 |
4126 |
Earlier Is Better & Combination Is Better |
Hwan-Cheol Park |
Apr. 12. 21 |
4125 |
What Is Your Choice for Adherance Hypertensive Patients with Dyslipidemia? |
Duk-Woo Park |
Apr. 12. 21 |
4124 |
Learn from Practice : Optimal PCI Treatment for HBR Patients |
Wonjae Lee |
Apr. 12. 21 |
4123 |
Potent P2Y12 Inhibitors for East-Asian Patients: Insights from the TWIGHLIGHT in Western vs. Asian Population |
Roxana Mehran |
Apr. 12. 21 |
4122 |
\"Less is More\" in Antithrombotic Therapy After PCI: Clinically Relevant not only in East-Asian but also in Western Population |
Takeshi Kimura |
Apr. 12. 21 |
4121 |
Antithrombotic Therapy in East Asian with ACS/PCI: Updated Evidences for East-Asian Paradox |
Glenn N. Levine |
Apr. 12. 21 |
4120 |
Composite Outcomes and Net Adverse Events: Implications for Trial Design and Interpretation |
David Joel Cohen |
Apr. 12. 21 |